The ALIAS (ALbumin in Acute Stroke) Phase III randomized multicentre clinical trial

Design and progress report

Myron Ginsberg, Y. Y. Palesch, M. D. Hill

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

High-dose human ALB (albumin) therapy is highly neuroprotective in animal models of ischaemic stroke. A recently completed 82-subject pilot-phase dose-escalation trial has shown that ALB is safe, with strong preliminary suggestions of possible efficacy. We are now proceeding to a large randomized, double-blinded, placebo-controlled multicentre trial funded by the NIH (National Institutes of Health), the ALIAS (Albumin In Acute Stroke) Phase III Trial, which is designed to ascertain definitively whether high-dose ALB therapy confers neuroprotection in subjects with acute ischaemic stroke treated within 5 h of stroke onset. The primary efficacy outcome measure is a favourable outcome, defined as an NIHSS (NIH Stroke Scale) score of 0-1 or a modified Rankin Scale score of 0-1 at 3 months post-randomization. Separate randomization (1:1) to ALB or placebo therapy will be carried out in two cohorts of 900 subjects each, one that receives standard-of-care thrombolytic therapy and the other that does not. Approx. 60 North American clinical sites will participate. Subject enrolment is expected to commence in July 2006.

Original languageEnglish
Pages (from-to)1323-1326
Number of pages4
JournalBiochemical Society Transactions
Volume34
Issue number6
DOIs
StatePublished - Dec 1 2006

Fingerprint

Phase III Clinical Trials
Multicenter Studies
Albumins
Randomized Controlled Trials
Stroke
National Institutes of Health (U.S.)
Random Allocation
Placebos
Health
Thrombolytic Therapy
Standard of Care
Animals
Therapeutics
Animal Models
Outcome Assessment (Health Care)

Keywords

  • Albumin
  • Focal cerebral ischaemia
  • Neuroprotection
  • Randomized clinical trial
  • Stroke
  • Thrombolysis

ASJC Scopus subject areas

  • Biochemistry

Cite this

The ALIAS (ALbumin in Acute Stroke) Phase III randomized multicentre clinical trial : Design and progress report. / Ginsberg, Myron; Palesch, Y. Y.; Hill, M. D.

In: Biochemical Society Transactions, Vol. 34, No. 6, 01.12.2006, p. 1323-1326.

Research output: Contribution to journalArticle

@article{ea2d777bbb174c5ba9a691e17a9dee78,
title = "The ALIAS (ALbumin in Acute Stroke) Phase III randomized multicentre clinical trial: Design and progress report",
abstract = "High-dose human ALB (albumin) therapy is highly neuroprotective in animal models of ischaemic stroke. A recently completed 82-subject pilot-phase dose-escalation trial has shown that ALB is safe, with strong preliminary suggestions of possible efficacy. We are now proceeding to a large randomized, double-blinded, placebo-controlled multicentre trial funded by the NIH (National Institutes of Health), the ALIAS (Albumin In Acute Stroke) Phase III Trial, which is designed to ascertain definitively whether high-dose ALB therapy confers neuroprotection in subjects with acute ischaemic stroke treated within 5 h of stroke onset. The primary efficacy outcome measure is a favourable outcome, defined as an NIHSS (NIH Stroke Scale) score of 0-1 or a modified Rankin Scale score of 0-1 at 3 months post-randomization. Separate randomization (1:1) to ALB or placebo therapy will be carried out in two cohorts of 900 subjects each, one that receives standard-of-care thrombolytic therapy and the other that does not. Approx. 60 North American clinical sites will participate. Subject enrolment is expected to commence in July 2006.",
keywords = "Albumin, Focal cerebral ischaemia, Neuroprotection, Randomized clinical trial, Stroke, Thrombolysis",
author = "Myron Ginsberg and Palesch, {Y. Y.} and Hill, {M. D.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1042/BST0341323",
language = "English",
volume = "34",
pages = "1323--1326",
journal = "Biochemical Society Transactions",
issn = "0300-5127",
publisher = "Portland Press Ltd.",
number = "6",

}

TY - JOUR

T1 - The ALIAS (ALbumin in Acute Stroke) Phase III randomized multicentre clinical trial

T2 - Design and progress report

AU - Ginsberg, Myron

AU - Palesch, Y. Y.

AU - Hill, M. D.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - High-dose human ALB (albumin) therapy is highly neuroprotective in animal models of ischaemic stroke. A recently completed 82-subject pilot-phase dose-escalation trial has shown that ALB is safe, with strong preliminary suggestions of possible efficacy. We are now proceeding to a large randomized, double-blinded, placebo-controlled multicentre trial funded by the NIH (National Institutes of Health), the ALIAS (Albumin In Acute Stroke) Phase III Trial, which is designed to ascertain definitively whether high-dose ALB therapy confers neuroprotection in subjects with acute ischaemic stroke treated within 5 h of stroke onset. The primary efficacy outcome measure is a favourable outcome, defined as an NIHSS (NIH Stroke Scale) score of 0-1 or a modified Rankin Scale score of 0-1 at 3 months post-randomization. Separate randomization (1:1) to ALB or placebo therapy will be carried out in two cohorts of 900 subjects each, one that receives standard-of-care thrombolytic therapy and the other that does not. Approx. 60 North American clinical sites will participate. Subject enrolment is expected to commence in July 2006.

AB - High-dose human ALB (albumin) therapy is highly neuroprotective in animal models of ischaemic stroke. A recently completed 82-subject pilot-phase dose-escalation trial has shown that ALB is safe, with strong preliminary suggestions of possible efficacy. We are now proceeding to a large randomized, double-blinded, placebo-controlled multicentre trial funded by the NIH (National Institutes of Health), the ALIAS (Albumin In Acute Stroke) Phase III Trial, which is designed to ascertain definitively whether high-dose ALB therapy confers neuroprotection in subjects with acute ischaemic stroke treated within 5 h of stroke onset. The primary efficacy outcome measure is a favourable outcome, defined as an NIHSS (NIH Stroke Scale) score of 0-1 or a modified Rankin Scale score of 0-1 at 3 months post-randomization. Separate randomization (1:1) to ALB or placebo therapy will be carried out in two cohorts of 900 subjects each, one that receives standard-of-care thrombolytic therapy and the other that does not. Approx. 60 North American clinical sites will participate. Subject enrolment is expected to commence in July 2006.

KW - Albumin

KW - Focal cerebral ischaemia

KW - Neuroprotection

KW - Randomized clinical trial

KW - Stroke

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=34248639061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248639061&partnerID=8YFLogxK

U2 - 10.1042/BST0341323

DO - 10.1042/BST0341323

M3 - Article

VL - 34

SP - 1323

EP - 1326

JO - Biochemical Society Transactions

JF - Biochemical Society Transactions

SN - 0300-5127

IS - 6

ER -